These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 8168083)

  • 41. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regression of LNCaP human prostate tumor xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation.
    Dahiya R; Zhang DY; Ho RJ; Haughney PC; Hayward SW; Cunha GR; Narayan P
    Biochem Mol Biol Int; 1995 Mar; 35(3):487-98. PubMed ID: 7773185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
    Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model.
    Bisanz K; Yu J; Edlund M; Spohn B; Hung MC; Chung LW; Hsieh CL
    Mol Ther; 2005 Oct; 12(4):634-43. PubMed ID: 16039164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice.
    Berlin O; Samid D; Donthineni-Rao R; Akeson W; Amiel D; Woods VL
    Cancer Res; 1993 Oct; 53(20):4890-5. PubMed ID: 8402677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
    Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
    Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved metastatic animal model of human prostate carcinoma using surgical orthotopic implantation (SOI).
    Chang XH; Fu YW; Na WL; Wang J; Sun H; Cai L
    Anticancer Res; 1999; 19(5B):4199-202. PubMed ID: 10628375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PC-1/PrLZ contributes to malignant progression in prostate cancer.
    Zhang H; Wang J; Pang B; Liang RX; Li S; Huang PT; Wang R; Chung LW; Zhau HE; Huang C; Zhou JG
    Cancer Res; 2007 Sep; 67(18):8906-13. PubMed ID: 17875733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
    Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
    Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of C4-2 prostate cancer bone metastases and their response to castration.
    Pfitzenmaier J; Quinn JE; Odman AM; Zhang J; Keller ET; Vessella RL; Corey E
    J Bone Miner Res; 2003 Oct; 18(10):1882-8. PubMed ID: 14584899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.
    Hyytinen ER; Thalmann GN; Zhau HE; Karhu R; Kallioniemi OP; Chung LW; Visakorpi T
    Br J Cancer; 1997; 75(2):190-5. PubMed ID: 9010025
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LNCaP model of human prostatic carcinoma.
    Horoszewicz JS; Leong SS; Kawinski E; Karr JP; Rosenthal H; Chu TM; Mirand EA; Murphy GP
    Cancer Res; 1983 Apr; 43(4):1809-18. PubMed ID: 6831420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.
    Thalmann GN; Rhee H; Sikes RA; Pathak S; Multani A; Zhau HE; Marshall FF; Chung LW
    Eur Urol; 2010 Jul; 58(1):162-71. PubMed ID: 19747763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel.
    Rhee HW; Zhau HE; Pathak S; Multani AS; Pennanen S; Visakorpi T; Chung LW
    In Vitro Cell Dev Biol Anim; 2001 Mar; 37(3):127-40. PubMed ID: 11370803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metastatic model for human prostate cancer using orthotopic implantation in nude mice.
    Stephenson RA; Dinney CP; Gohji K; Ordóñez NG; Killion JJ; Fidler IJ
    J Natl Cancer Inst; 1992 Jun; 84(12):951-7. PubMed ID: 1378502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical, cytogenetic, and morphological characteristics of human primary and metastatic prostate cancer cell lines.
    Dahiya R; Yoon WH; Boyle B; Schoenberg S; Yen TS; Narayan P
    Biochem Int; 1992 Aug; 27(4):567-77. PubMed ID: 1417893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Dunning tumors.
    Lubaroff DM; Canfield L; Reynolds CW
    Prog Clin Biol Res; 1980; 37():243-63. PubMed ID: 6247719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.
    Burchardt M; Burchardt T; Shabsigh A; Ghafar M; Chen MW; Anastasiadis A; de la Taille A; Kiss A; Buttyan R
    Prostate; 2001 Sep; 48(4):225-30. PubMed ID: 11536301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid detection of candidate metastatic foci in the orthotopic inoculation model of androgen-sensitive prostate cancer cells introduced with green fluorescent protein.
    Maeda H; Segawa T; Kamoto T; Yoshida H; Kakizuka A; Ogawa O; Kakehi Y
    Prostate; 2000 Dec; 45(4):335-40. PubMed ID: 11102959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.